RU2577700C2 - Фармацевтическая комбинация для лечения опухоли - Google Patents

Фармацевтическая комбинация для лечения опухоли Download PDF

Info

Publication number
RU2577700C2
RU2577700C2 RU2012114771/15A RU2012114771A RU2577700C2 RU 2577700 C2 RU2577700 C2 RU 2577700C2 RU 2012114771/15 A RU2012114771/15 A RU 2012114771/15A RU 2012114771 A RU2012114771 A RU 2012114771A RU 2577700 C2 RU2577700 C2 RU 2577700C2
Authority
RU
Russia
Prior art keywords
hydroxy
group
ether
alkyl
heptanoic acid
Prior art date
Application number
RU2012114771/15A
Other languages
English (en)
Russian (ru)
Other versions
RU2012114771A (ru
Inventor
Рюдзи УЭНО
Original Assignee
Сукампо Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Сукампо Аг filed Critical Сукампо Аг
Publication of RU2012114771A publication Critical patent/RU2012114771A/ru
Application granted granted Critical
Publication of RU2577700C2 publication Critical patent/RU2577700C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/558—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
RU2012114771/15A 2009-09-16 2010-09-16 Фармацевтическая комбинация для лечения опухоли RU2577700C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24301909P 2009-09-16 2009-09-16
US61/243,019 2009-09-16
PCT/JP2010/066619 WO2011034210A1 (en) 2009-09-16 2010-09-16 Pharmaceutical combination for treating tumor

Related Child Applications (1)

Application Number Title Priority Date Filing Date
RU2016103415A Division RU2016103415A (ru) 2009-09-16 2010-09-16 Фармацевтическая комбинация для лечения опухоли

Publications (2)

Publication Number Publication Date
RU2012114771A RU2012114771A (ru) 2013-10-27
RU2577700C2 true RU2577700C2 (ru) 2016-03-20

Family

ID=43730802

Family Applications (2)

Application Number Title Priority Date Filing Date
RU2012114771/15A RU2577700C2 (ru) 2009-09-16 2010-09-16 Фармацевтическая комбинация для лечения опухоли
RU2016103415A RU2016103415A (ru) 2009-09-16 2010-09-16 Фармацевтическая комбинация для лечения опухоли

Family Applications After (1)

Application Number Title Priority Date Filing Date
RU2016103415A RU2016103415A (ru) 2009-09-16 2010-09-16 Фармацевтическая комбинация для лечения опухоли

Country Status (17)

Country Link
US (3) US9084815B2 (https=)
EP (1) EP2477632A4 (https=)
JP (2) JP5891168B2 (https=)
KR (1) KR101760963B1 (https=)
CN (2) CN107050458A (https=)
AR (1) AR078182A1 (https=)
AU (1) AU2010296307B2 (https=)
BR (1) BR112012005896A2 (https=)
CA (1) CA2772314A1 (https=)
IL (1) IL218392A (https=)
MX (1) MX2012003188A (https=)
NZ (1) NZ598618A (https=)
RU (2) RU2577700C2 (https=)
SG (2) SG179153A1 (https=)
TW (1) TWI535436B (https=)
WO (1) WO2011034210A1 (https=)
ZA (1) ZA201201894B (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014159679A1 (en) 2013-03-12 2014-10-02 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Methods for using lubiprostone to absorb fluid from the subretinal space
US20150099802A1 (en) * 2013-10-03 2015-04-09 Sucampo Ag Selective tumor treatment

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996003992A1 (en) * 1994-08-04 1996-02-15 Loyola University Of Chicago Protective prostaglandins for use in conjunction with chemotherapeutic agents
RU2071780C1 (ru) * 1993-10-11 1997-01-20 Научно-производственное предприятие "Фармэк" Способ лечения медикаментозных эзофаго-гингиво-стоматитов
WO2006101244A2 (en) * 2005-03-21 2006-09-28 Sucampo Ag Method and composition for treating mucosal disorders

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1322749C (en) * 1987-01-28 1993-10-05 Ryuzo Ueno Prostaglandins of the d series, and tranquilizers and soporifics containing the same
US5166174A (en) * 1987-01-28 1992-11-24 K.K. Ueno Seiyaku Oyo Kenkyujo Prostaglandins E and anti-ulcers containing same
US5221763A (en) * 1987-04-30 1993-06-22 R-Tech Ueno, Ltd. Prostaglandins of the F series
TW224942B (https=) * 1990-04-04 1994-06-11 Adka Ueno Kk
DK0454429T3 (da) 1990-04-27 1997-03-17 R Tech Ueno Ltd Anvendelse af 15-dehydroxy-16-oxoprostaglandinderivater til behandling af allergiske sygdomme
US5302617A (en) * 1990-04-27 1994-04-12 Kabushikikaisha Ueno Seiyaku Oyo Kenkyuio Biochemical treatment with 15-dehydroxy-16-oxoprostaglandin compounds
US5438075A (en) * 1993-03-30 1995-08-01 Skubitz; Keith M. Oral glutamine to reduce stomatitis
JPH0770054A (ja) 1993-08-30 1995-03-14 R Tec Ueno:Kk 生化学的拮抗および疾患処置剤
CA2150287C (en) * 1994-06-03 2004-08-10 Ryuji Ueno Agent for treating hepato-biliary diseases
JP3187438B2 (ja) * 1996-06-10 2001-07-11 株式会社アールテック・ウエノ エンドセリン拮抗剤
EP1267882B1 (en) 2000-03-24 2009-04-15 Sucampo AG Prostaglandins for the treatment of eye disease caused by light irradiation like photoretinitis
US6414016B1 (en) * 2000-09-05 2002-07-02 Sucampo, A.G. Anti-constipation composition
TWI302100B (en) 2001-05-02 2008-10-21 Sucampo Ag Composition for treating drug-induced constipation
ATE489096T1 (de) * 2003-07-03 2010-12-15 Sucampo Ag Pharmazeutische magensaftresistent überzogene zusammensetzung enthaltend prostaglandin-analoga als chloridkanalöffner
DK1841433T3 (da) 2005-01-27 2012-01-16 Sucampo Ag Præparat til behandling af lidelser i centralnervesystemet
CN101180096B (zh) * 2005-03-21 2015-04-22 苏坎波公司 用于治疗粘膜疾病的方法和组合物
US20090012165A1 (en) * 2007-07-03 2009-01-08 Sucampo Ag Pharmaceutical combination of nsaid and prostaglandin compound

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2071780C1 (ru) * 1993-10-11 1997-01-20 Научно-производственное предприятие "Фармэк" Способ лечения медикаментозных эзофаго-гингиво-стоматитов
WO1996003992A1 (en) * 1994-08-04 1996-02-15 Loyola University Of Chicago Protective prostaglandins for use in conjunction with chemotherapeutic agents
WO2006101244A2 (en) * 2005-03-21 2006-09-28 Sucampo Ag Method and composition for treating mucosal disorders

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
I. Kuhrer et al. TOPICAL PGE2 ENHANCES HEALING OF CHEMOTHERAPY-ASSOCIATED MUCOSAL LESIONS// The Lancet. 1986. Mar 15;1(8481):623. *
Maltoni M et al. Topical prostaglandin E2 and chemo- and radio-induced oral mucositis // Oncol Rep. 1996 Jan;3(1):205-208. *

Also Published As

Publication number Publication date
NZ598618A (en) 2014-10-31
RU2016103415A (ru) 2018-11-22
WO2011034210A1 (en) 2011-03-24
ZA201201894B (en) 2012-11-28
CA2772314A1 (en) 2011-03-24
US20110064748A1 (en) 2011-03-17
AU2010296307A1 (en) 2012-04-05
AU2010296307B2 (en) 2016-02-11
US20150272961A1 (en) 2015-10-01
EP2477632A1 (en) 2012-07-25
TW201116277A (en) 2011-05-16
RU2012114771A (ru) 2013-10-27
EP2477632A4 (en) 2013-06-12
JP2016056191A (ja) 2016-04-21
SG179153A1 (en) 2012-04-27
BR112012005896A2 (pt) 2016-03-15
KR101760963B1 (ko) 2017-07-24
IL218392A (en) 2016-05-31
TWI535436B (zh) 2016-06-01
JP2013504520A (ja) 2013-02-07
MX2012003188A (es) 2012-04-30
IL218392A0 (en) 2012-04-30
CN107050458A (zh) 2017-08-18
KR20120081139A (ko) 2012-07-18
US9084815B2 (en) 2015-07-21
AR078182A1 (es) 2011-10-19
SG10201405467PA (en) 2014-10-30
CN102481302A (zh) 2012-05-30
JP5891168B2 (ja) 2016-03-22
US20170079986A1 (en) 2017-03-23

Similar Documents

Publication Publication Date Title
KR100886598B1 (ko) 15-케토-프로스타글란딘을 가지는, 약물-유발 변비 치료용조성물
HUP0302422A2 (hu) Hashajtó hatású kompozíció és alkalmazása gyógyszer előállítására
AU2002251554A1 (en) Composition for Treating Drug-Induced Constipation
JP2010532314A (ja) Ｎｓａｉｄおよびプロスタグランジン化合物の医薬的組み合わせ
BRPI0317740B1 (pt) uso do composto 13,14-diidro-15-ceto-16,16-diflúorprostaglandina e1
RU2577700C2 (ru) Фармацевтическая комбинация для лечения опухоли
CN1443070A (zh) 包含15－酮基－前列腺素或其衍生物的编程性细胞死亡抑制组合物
JP2017048255A (ja) オピオイドおよびプロスタグランジン化合物の医薬的組み合わせ
JP2012524025A (ja) 黄斑変性を処置するための方法および組成物
US20100305203A1 (en) Method for modulating claudin mediated functions
WO2015025980A1 (en) Method for treating neuropathic pain
US8569279B2 (en) Method for modulating claudin mediated functions
US20160120840A1 (en) Method and composition for treating nonerosive reflux disease
JP2015514681A (ja) 下痢を伴う過敏性腸症候群の処置方法
JP2014515004A (ja) イオン輸送体の調節方法

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20170917